AIDS TREATMENT NEWS Issue #213, December 23, 1994
John S. James
This association does not necessarily mean that the virus causes KS -- since it could be a normally-occurring virus which preferentially grows in KS tissue. But if the virus does cause KS, the finding will be very important for developing treatments, for diagnostic tests to tell who is at risk, and for epidemiological studies to prevent the spread of the virus. It is not known whether or not the new virus is sensitive to any existing drugs.
Researchers have long believed that KS is not a true cancer -- and that it is probably caused by an infectious agent other than HIV, but is unlikely to become a serious problem except in those who are immune compromised. It is 20 times more likely to be found in gay men with AIDS than in hemophiliacs with AIDS, and may be transmitted (separately from HIV) by unsafe sexual practices.
The new research used an advanced biotechnology technique called representational difference analysis (RDA). In RDA, two different tissues are taken from the same patient -- in this case from a KS lesions, vs. tissue without KS. RDA uses gene amplification (PCR) in a special way, in order to find genetic sequences which are uniquely present in the tissue of interest. (Once such a sequence is identified, more conventional techniques can be used to identify it in other tissue samples.)
The paper describing the research appeared in SCIENCE, December 16. The NEW YORK TIMES reported that the editors of SCIENCE took five months to examine the data, to be especially careful to make sure the results were valid. There is skepticism about the reasons for the delay.
This research was funded by Columbia University's Department of Pathology, and School of Public Health.
Comment: Foscarnet, Call for Information
At the Second International Congress on Drug Therapy in HIV Infection, last month in Glasgow, Scotland, a physician in the audience reported that several KS patients had improved when treated with foscarnet (Foscavir), an approved drug usually used for treating CMV infection. According to NURSING 94 DRUG HANDBOOK, foscarnet inhibits all known herpesviruses in laboratory tests. Unfortunately foscarnet must be given intravenously, and it can cause serious toxicities.
We heard that some KS experts scoffed at these case reports, because the information was not from a controlled trial. They probably did know about the Columbia findings, which were not public at the time of the Glasgow meeting but were discussed privately there.
If you know of any case in which a person with KS has used foscarnet, regardless of whether or not there seemed to be any effect on the KS, please contact John S. James at AIDS TREATMENT NEWS, 415/255-0588, or fax to 415/255-4659.
References
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, and Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. SCIENCE. 1994; volume 266, pages 1865-1869.
941223
ATN21301
Copyright © 1994 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .